Get the Stockscreener App
82.45
1.23%
-1.03
After Hours:
82.45
Edwards Lifesciences Corp stock is traded at $82.45, with a volume of 11.51M.
It is down -1.23% in the last 24 hours and up +6.02% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$83.48
Open:
$84.48
24h Volume:
11.51M
Relative Volume:
2.60
Market Cap:
$48.41B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
35.15
EPS:
2.3455
Net Cash Flow:
$577.90M
1W Performance:
+8.34%
1M Performance:
+6.02%
6M Performance:
+9.22%
1Y Performance:
+23.04%
1-Day Range:
$81.49
$87.09
1-Week Range:
$75.48
$87.09
52-Week Range:
$64.89
$87.09
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.88B | 1.34B | 577.90M | 2.3455 |
|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Will Edwards Lifesciences Corporation (EWL) stock test record highs in 20252025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Strs Ohio Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Amalgamated Bank Has $8.86 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation stock trend forecast2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Edwards Lifesciences Corporation (NYSE:EW) Q3 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 at Royal Bank Of Canada - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $92.00 - MarketBeat
Mccarter Private Wealth Services LLC Reduces Position in Edwards Lifesciences Corporation $EW - MarketBeat
Lockheed Martin Investment Management Co. Has $4.34 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Fisher Funds Management LTD Has $74.16 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Using data models to predict Edwards Lifesciences Corporation stock movementWeekly Trend Summary & Risk Controlled Stock Pick Alerts - newser.com
Spire Wealth Management Raises Position in Edwards Lifesciences Corporation $EW - MarketBeat
What is the fair value of Edwards Lifesciences Corporation stock nowJuly 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
Quantitative breakdown of Edwards Lifesciences Corporation recent moveMarket Performance Report & Weekly Sector Rotation Insights - newser.com
Is Edwards Lifesciences Corporation (EWL) stock positioned for secular growth2025 Retail Activity & Stock Market Timing Techniques - newser.com
Edwards Lifesciences Topped Estimates As Demand For Heart Devices Rose - Finimize
Edwards Lifesciences Reports Strong Earnings and Growth - TipRanks
Edwards Lifesciences (NYSE:EW) Updates Q4 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results - MarketBeat
Edwards Lifesciences Lifts Outlook After Topping Expectations - Finimize
Edwards Lifesciences’ ALTERRA Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences (EW) Target Price Raised by Barclays to $99 - GuruFocus
Citigroup Raises Price Target for Edwards Lifesciences (EW) to $96 | EW Stock News - GuruFocus
Edwards Lifesciences (EW): Analyst Updates and Raised Price Targ - GuruFocus
Goldman Sachs Raises Price Target for Edwards Lifesciences (EW) to $104 | EW Stock News - GuruFocus
Canaccord Genuity Raises Edwards Lifesciences' Price Target to $84 From $81 - MarketScreener
Piper Sandler Raises Edwards Lifesciences (EW) Price Target to $95 | EW Stock News - GuruFocus
RBC Capital Raises Price Target for Edwards Lifesciences (EW) to $95.00 | EW Stock News - GuruFocus
Stifel Raises Edwards Lifesciences (EW) Price Target to $95 with Buy Rating | EW Stock News - GuruFocus
Evercore ISI Group Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $88 From $84 - MarketScreener
Citigroup Adjusts Price Target on Edwards Lifesciences to $96 From $95 - MarketScreener
Stifel Adjusts Price Target on Edwards Lifesciences to $95 From $85 - MarketScreener
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $95 From $88 - MarketScreener
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $92 From $88 - MarketScreener
TD Cowen Adjusts Price Target on Edwards Lifesciences to $90 From $84 - MarketScreener
Rothschild & Co Redburn Adjusts Price Target on Edwards Lifesciences to $93 From $85 - MarketScreener
Barclays Adjusts Price Target on Edwards Lifesciences to $99 From $95 - MarketScreener
Deutsche Bank Adjusts Price Target on Edwards Lifesciences to $100 From $94 - MarketScreener
JPMorgan Adjusts Price Target on Edwards Lifesciences to $90 From $85 - MarketScreener
Jefferies Adjusts Price Target on Edwards Lifesciences to $102 From $98 - MarketScreener
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $104 From $94 - MarketScreener
Edwards Lifesciences (NYSE:EW) Rating Increased to Buy at Jefferies Financial Group - MarketBeat
World Investment Advisors Has $4.78 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences Corporation stock a good choice for value investorsJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Will Edwards Lifesciences Corporation stock return to pre crash levelsBond Market & Low Drawdown Trading Strategies - newser.com
What dividend safety score for Edwards Lifesciences Corporation stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Using Python tools to backtest Edwards Lifesciences Corporation strategiesWeekly Stock Report & High Return Trade Guides - newser.com
Earnings call transcript: Edwards Lifesciences beats Q3 2025 earnings expectations By Investing.com - Investing.com Canada
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):